Inovio Pharmaceuticals’ (INO) Market Outperform Rating Reiterated at JMP Securities

Inovio Pharmaceuticals (NASDAQ:INO)‘s stock had its “market outperform” rating reaffirmed by stock analysts at JMP Securities in a note issued to investors on Friday,Benzinga reports. They currently have a $18.00 price target on the biopharmaceutical company’s stock.

Other equities research analysts also recently issued reports about the stock. Oppenheimer cut their target price on shares of Inovio Pharmaceuticals from $33.00 to $15.00 and set an “outperform” rating on the stock in a research note on Monday, November 18th. Royal Bank of Canada cut their price target on Inovio Pharmaceuticals from $7.00 to $6.00 and set a “sector perform” rating on the stock in a research report on Friday, November 15th. Finally, HC Wainwright lowered their price target on Inovio Pharmaceuticals from $12.00 to $5.00 and set a “neutral” rating on the stock in a report on Monday, November 18th. One analyst has rated the stock with a sell rating, two have issued a hold rating and three have issued a buy rating to the stock. Based on data from MarketBeat, the stock has an average rating of “Hold” and an average price target of $12.80.

Inovio Pharmaceuticals Stock Performance

NASDAQ INO traded down $0.06 during trading on Friday, hitting $2.03. The stock had a trading volume of 269,791 shares, compared to its average volume of 1,810,009. The firm has a 50 day moving average price of $3.55 and a 200 day moving average price of $6.18. Inovio Pharmaceuticals has a twelve month low of $1.74 and a twelve month high of $14.75.

Institutional Investors Weigh In On Inovio Pharmaceuticals

Several institutional investors and hedge funds have recently made changes to their positions in the business. BNP Paribas Financial Markets grew its stake in Inovio Pharmaceuticals by 177.0% in the 3rd quarter. BNP Paribas Financial Markets now owns 5,681 shares of the biopharmaceutical company’s stock worth $33,000 after acquiring an additional 3,630 shares during the period. MetLife Investment Management LLC increased its stake in Inovio Pharmaceuticals by 129.1% in the third quarter. MetLife Investment Management LLC now owns 15,167 shares of the biopharmaceutical company’s stock valued at $88,000 after purchasing an additional 8,546 shares during the last quarter. The Manufacturers Life Insurance Company acquired a new stake in Inovio Pharmaceuticals in the 2nd quarter worth about $82,000. American Century Companies Inc. grew its holdings in Inovio Pharmaceuticals by 62.2% in the 2nd quarter. American Century Companies Inc. now owns 31,565 shares of the biopharmaceutical company’s stock valued at $255,000 after buying an additional 12,100 shares during the period. Finally, SG Americas Securities LLC acquired a new position in shares of Inovio Pharmaceuticals during the 3rd quarter valued at about $71,000. 26.79% of the stock is currently owned by hedge funds and other institutional investors.

About Inovio Pharmaceuticals

Inovio Pharmaceuticals, Inc, a biotechnology company, focuses on the discovery, development, and commercialization of DNA medicines to treat and protect people from diseases associated with human papillomavirus (HPV), cancer, and infectious diseases. Its DNA medicines platform uses precisely designed SynCon that identify and optimize the DNA sequence of the target antigen, as well as CELLECTRA smart devices technology that facilitates delivery of the DNA plasmids.